VBL Therapeutics Reports Will Present Data On Novel MOSPD2 Program In Oncology, Inflammation At BIO Convention; Highlights Data Indicating MOSPD2 Is Required For Directional Movement Of Tumor cells, Certain Immune Cells
Benzinga Newsdesk